According to Abhishek Karande of SBICap Securities, one may avoid Aurobindo Pharma and advises picking Cipla or Divis Laboratories.
first published: Dec 19, 2013 03:51 pm
A collection of the most-viewed Moneycontrol videos.
Live: Banking stocks fuel Nifty above 24,500; Uncertainty persists on US-Iran talks | Closing Bell
JD Vance May Visit Pakistan For Second Round Of Peace Talks With Iran: Reports
Trump Claims Iran N-Sites ‘Obliterated’: ‘Digging Nuclear Dust Won’t Be Easy’
PAN Misuse Alert | How to Check If Someone Opened Bank Accounts in Your Name
